Consortia for Structure-based Immunogen Design for HIV (CSID-HIV) (UM1 Clinical Trial Not Allowed)

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking to support research for structure-based immunogen design to advance the development and selection of HIV immunogens that induce broadly neutralizing antibody (bNAb) responses. The goal is to achieve proof of concept of therapeutic strategies using bNABs and vaccine-induction of bNAbs targeting multiple bNAb sites. The technology being developed through these consortia will be applicable to other fields facing significant hurdles in viral antigen therapeutic targeting and vaccine design. • The opportunity is focused on HIV immunogen design and development. • The research should address critical immunogen design roadblocks in discovering and developing safe and effective HIV bNAbs and bNAb responses. • The technology being developed will be applicable to other fields facing significant hurdles in viral antigen therapeutic targeting and vaccine design. • The opportunity will support coordinated multidisciplinary efforts on bNAb and vaccine discovery and applied research.